HV Healthcare
The Techbio future of healthcare.
The Healthcare industry is undergoing a profound transformation, driven by advancements in technology, changing demographics, and evolving patient needs. Our healthcare portfolio recognizes the immense potential of healthcare innovation to improve patient outcomes, enhance access to care, and drive operational efficiency.
Areas of interest include: AI-driven drug discovery, multi-omics approaches and precision medicine, synthetic biology and biological systems modeling, bioengineering and biomanufacturing.
We look for:
Platform Technology with Strong Data Moat:
We firmly believe in the transformative power of platform technologies, especially when paired with a unique and highly diverse dataset, to unlock groundbreaking insights and drive exponential impact.
Interdisciplinary Teams:
Healthcare is evolving from chance-based discovery to computation-driven engineering. We are excited to partner with interdisciplinary teams that combine expertise in software and biology, seamlessly merging data science with biological insights.
Focusing on New Business Models:
The future of healthcare is being reshaped by innovative business models that integrate AI and software with biotechnology and bioengineering. We are passionate about working with pioneering approaches, leveraging the power of AI to build scalable solutions, optimize workflows, and deliver precision, data-driven healthcare at scale.
ArsenalBio develops programmable CAR-T therapies using genetic circuits, CRISPR, AI, and data analytics for cancer treatment
ArsenalBio develops programmable cell therapies using genetic circuits to enhance CAR-T therapies for solid tumors. By controlling specificity, on-tumor activation, potency, and durability, the company leverages CRISPR, AI, and data analytics to reprogram T cells and identify new drug candidates for improved cancer treatment.
CEO
Ken Drazan
Sectors
Healthcare
Stage
Series C
HQ
California
Deal Team
Wolfgang Seibold
Joanna Soroka
Bioptimus is building a universal multi-scale, multi-modal Foundation Model for Biology to revolutionize biomedicine research.
Bioptimus is building the world’s first universal multi-scale, multi-modal Foundation Model for Biology. By leveraging expertise from Google DeepMind and the unique MOSAIC dataset, Bioptimus aims to uncover intricate relationships across biological systems at unprecedented scales. This groundbreaking approach is poised to drive the next frontier in biomedicine research.
CEO
Jean-Philippe Vert
Sectors
Digital
Healthcare
Stage
Series A
HQ
Paris
Deal Team
Wolfgang Seibold
Joanna Soroka
Marina Du
Cure51 is building the first global database of cancer survivors to uncover new life-saving medicines.
Cure51 is creating the world’s first global, diversified clinical and molecular database of cancer survivors to uncover life-saving medicines. Through a collaborative network, multiomics, and special biology, it aims to identify therapeutic targets for cancer treatment. The company, co-created with oncology centers, focuses on three cancer indications.
CEO
Nicolas Wolikow
Sectors
Healthcare
Stage
Seed
HQ
Paris
Deal Team
Wolfgang Seibold
Joanna Soroka
Marina Du
Digital health platform using real-time health data to improve clinical care and research
Digital health platform enabling ‘Hospital at Home’ remotely collect patient-generated data, greater access to care outside of a conventional setting, improving efficiency and empowering patients to better manage their own health Companion App (SaMD) secure, scalable and fully compliant platform accelerates time to market for pharma and medtech customers’ regulated digital health products
Digital Clinical Trial (DCT) easy-to-build and digital-first clinical trial platform that deploys trial at speed, achieve higher accuracy with continuous data collection and near real-time reporting.
CEO
Dan Vahdat
Sectors
Digital
Healthcare
Stage
Series D
HQ
London
Deal Team
Wolfgang Seibold
Fully-automated mass production of induced Pluripotent Stem Cells (iPSC) for clinical research
Develops technology that uses biotechnology approaches to simplify the process of generating iPSCs and automates the preparation process using advanced robotics and fluidics technology
Their proprietary manufacturing platform enables fully-automated mass production of discrete iPSCs. Provides research-grade and clinical grade iPSCs for biotech companies in regenerative medicine iPSC banking service for consumers (B2C).
CEO
Koji Tanabe, Ph.D.
Sectors
Healthcare
Stage
Series B
HQ
California
Proscia’s AI-powered digital pathology platform enhances research, clinical workflows, and collaboration for biopharma and diagnostics.
Proscia’s Digital Pathology Platform, powered by AI applications, enhances efficiency and efficacy in research and clinical workflows. Concentriq connects image data and computational tools, serving biopharma as a system of record for R&D, while delivering efficient tissue analysis for CROs and enabling seamless collaboration for diagnostic labs.
CEO
David West
Sectors
Healthcare
Stage
Series C
HQ
Pennsylvania, USA
Deal Team
Pete Bastien
Joanna Soroka
Relation Therapeutics combines AI, genomic medicine, and Lab-in-the-Loop to build disease maps and discover novel drug targets.
Relation Therapeutics is a drug discovery company focused on genomics, combining advanced ActiveGraph AI models with Lab-in-the-Loop. This integration allows for seamless single-cell analysis at scale, creating rich maps of disease biology to identify novel drug targets. Their approach accelerates drug discovery by linking genomics and AI-driven insights.
CEO
David Roblin
Sectors
Digital
Healthcare
Stage
Seed
HQ
London
Deal Team
Wolfgang Seibold
Joanna Soroka
Marina Du
Scipher Medicine uses transcriptomics and network biology to uncover molecular signatures for autoimmune disease diagnostics and drug discovery.
Scipher Medicine leverages transcriptomics and real-world evidence to build a precision immunology platform for complex diseases. Combining interactome and network biology with proprietary patient transcriptomics data, the platform uncovers unique molecular disease signatures in autoimmune disease patients, advancing diagnostics, drug discovery, and personalized treatment development.
CEO
Reginald Seeto
Sectors
Healthcare
Stage
Series D
HQ
Massachusetts
Deal Team
Wolfgang Seibold
Joanna Soroka
Data analytics solution to support healthcare professionals by maximizing power of data-driven precision medicine.
Exited
Sophia Genetics offers a decentralized, AI-driven data analytics platform integrating genomics, radiology, and clinical data. Covering cancer, cardiology, nephropathies, and hereditary diseases, the platform connects over 750 global health institutions. It seamlessly integrates into existing workflows, ensuring data ownership while powering precision medicine and actionable insights for healthcare providers and biopharma.
CEO
Jurgi Camblong
Sectors
Healthcare
Stage
Exited
HQ
Massachusetts
Deal Team
Wolfgang Seibold
Wolfgang and the Hitachi team have truly felt like an extension of our own team. Whenever we reach out for help, they are always there—deeply committed to Huma’s mission and success, and unwaveringly consistent through all our ups and downs.
Dan Vahdat, Founder & CEO
Healthcare Perspectives
February 14, 2025
Why We Invested
Bioptimus: The GPT of Biology – Unlocking Deep Insights Across Biological Scales
January 14, 2025
Portfolio News
Bioptimus Hits $76M Funding Milestone and Prepares to Launch Groundbreaking Foundation Model for Biology
March 19, 2024
Portfolio News
Cure51 raises a €15M seed round aiming to crack the code on cancer survival
March 13, 2024
Portfolio News
Exclusive: ‘ChatGPT for DNA’: Relation nabs $35M, with Nvidia backing, for osteoporosis work
September 8, 2023
Portfolio News
Scipher Medicine Receives Medicare Coverage for PrismRA® Test in Rheumatoid Arthritis Patients
September 7, 2022
Why We Invested
Why Hitachi Ventures invested in ArsenalBio and their programmable autologous immune cell therapies for solid tumors
October 29, 2021
Portfolio News
The Galien Foundation Honors Excellence in Scientific Innovation at 2021 Prix Galien Awards Gala
Healthcare Perspectives
